Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.58 |
| ▸ | KIF11 | P52732 | 10/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272444 | 1.00 | PDE2A (0.58) | PDE2AKIF11AKR1C3AKR1C2PTPN5 | |
| SCHEMBL2272449 | 1.00 | PDE2A (0.58) | PDE2AKIF11AKR1C3AKR1C2PTPN5 | |
| SCHEMBL18075380 | 0.86 | PDE2A (0.77) | PDE2A | |
| SCHEMBL30134102 | 0.86 | PDE2A (0.77) | PDE2A | |
| SCHEMBL2268129 | 0.83 | PDE2A (0.54) | PDE2AKIF11AKR1C3AKR1C2PTPN5 | |
| SCHEMBL2268127 | 0.83 | PDE2A (0.54) | PDE2AKIF11AKR1C3AKR1C2PTPN5 | |
| SCHEMBL2268133 | 0.83 | PDE2A (0.54) | PDE2AKIF11AKR1C3AKR1C2PTPN5 | |
| SCHEMBL12603870 | 0.82 | PDE2A (0.76) | PDE2AKIF11AKR1C3AKR1C2PTPN5 | |
| SCHEMBL7949274 | 0.81 | FFAR1 (0.51) | PDE2AAKR1C3AKR1C2PTPN5PSEN1 | |
| SCHEMBL2272017 | 0.78 | PDE2A (0.59) | PDE2AKIF11AKR1C3AKR1C2PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758859-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | PDE2A 386/4885KIF11 3904/4885AKR1C3 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.